- Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada.
- Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA).
Vancouver, Canada – April 30, 2025 – Vancouver, Canada – May 2, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the SPARTAN 2025 Annual Meeting, taking place May 9–10, 2025, in Toronto, Canada. This premier event will bring together leading clinicians and researchers focused on advancing care for axial spondyloarthritis (axSpA).
At the meeting, Augurex will discuss SPINEstat™, a Health Canada-approved, first-in-class diagnostic blood test that detects Anti-14-3-3η autoantibodies. The test is designed to aid in the early diagnosis and ongoing monitoring of axSpA, particularly in cases where conventional tests like HLA-B27 may be insufficient.
Join us at SPARTAN 2025 to learn more about our commitment to advancing axSpA diagnostics and improving patient care.
For more details about the event, visit:
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
[email protected]